Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 昭衍新药
Other Market Stock Code603127
H-Share Offer PriceHK$ 151.00
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameJoinn
Stock Code06127
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities本公司是一家專注於藥物非臨床安全性評價的領先合同研究組織,正擴展以提供涵蓋藥物研發服務鏈上藥物發現、臨床前和臨床試驗階段的綜合服務,主要包括非臨床研究、臨床試驗及相關服務以及實驗模型業務。
Listing Date2021-02-26
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京經濟技術開發區榮京東街甲5號
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitejoinn-lab.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingYes (A股)

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 151.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 15,100
Par ValueRMB 1.0 / shares
Offer Period2021-02-16 to 2021-02-19
Global Offering Shares43,324,800 shares
HK Public Offer Shares (Initial)3,899,300 shares (9.0%)
Public Offer Lots (Initial)38,993lots (Pool A19,496lots,Pool B19,497lots)
International Placing Shares (Initial)39,425,500 shares (91.0%)
Offer Ratio~9.0%
Total Shares Post-IPO270,779,529 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share31.8%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 6,542,044,800

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 15,100
2 lots 200 HK$ 30,200
3 lots 300 HK$ 45,300
4 lots 400 HK$ 60,400
5 lots 500 HK$ 75,500
6 lots 600 HK$ 90,600
7 lots 700 HK$ 105,700
8 lots 800 HK$ 120,800
9 lots 900 HK$ 135,900
10 lots 1,000 HK$ 151,000
15 lots 1,500 HK$ 226,500
20 lots 2,000 HK$ 302,000
25 lots 2,500 HK$ 377,500
30 lots 3,000 HK$ 453,000
35 lots 3,500 HK$ 528,500
40 lots 4,000 HK$ 604,000
45 lots 4,500 HK$ 679,500
50 lots 5,000 HK$ 755,000
60 lots 6,000 HK$ 906,000
70 lots 7,000 HK$ 1,057,000
80 lots 8,000 HK$ 1,208,000
90 lots 9,000 HK$ 1,359,000
100 lots 10,000 HK$ 1,510,000
200 lots 20,000 HK$ 3,020,000
300 lots 30,000 HK$ 4,530,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
400 lots 40,000 HK$ 6,040,000
500 lots 50,000 HK$ 7,550,000
600 lots 60,000 HK$ 9,060,000
700 lots 70,000 HK$ 10,570,000
800 lots 80,000 HK$ 12,080,000
900 lots 90,000 HK$ 13,590,000
1,000 lots 100,000 HK$ 15,100,000
2,000 lots 200,000 HK$ 30,200,000
3,000 lots 300,000 HK$ 45,300,000
4,000 lots 400,000 HK$ 60,400,000
5,000 lots 500,000 HK$ 75,500,000
6,000 lots 600,000 HK$ 90,600,000
7,000 lots 700,000 HK$ 105,700,000
8,000 lots 800,000 HK$ 120,800,000
9,000 lots 900,000 HK$ 135,900,000
10,000 lots 1,000,000 HK$ 151,000,000
15,000 lots 1,500,000 HK$ 226,500,000
19,496 lots 1,949,600 HK$ 294,389,600

Stock Connect Inclusion Analysis

HK Market Cap HK$ 2.65B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 40,887,708,879
H-Share Market Cap (at Offer Price)HK$ 6,542,044,800
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣187.7百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201720182019
Profit before tax 97,419124,794216,759
Profit for the year 79,917105,471187,677
Profit attributable to owners 79,917105,320187,838
Balance Sheet
Item 2017201820192020-09
Cash and cash equivalents 254,617148,693176,958
Trade and bills receivables 40,54356,47697,388
Inventories 10,33812,96949,555
Total current assets 619,927714,502715,919
Total assets 974,1261,176,9761,570,141
Total current liabilities 323,106424,506554,051
Total liabilities 397,571509,556720,196
Total equity 576,555667,420849,945
Equity attributable to owners 576,203667,219849,200
Interest-bearing borrowings 0022,32326,227
Cash Flow Statement
Item 2017201820192020-09
Net cash from operating activities 118,320160,824148,939
Net cash from investing activities -220,530-252,045-103,723
Depreciation of PP&E 23,51927,31042,27750,798
Amortisation of intangible assets 5508532,3758,295
Purchase of PP&E -23,163-128,038-120,838-121,332
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 138.0
First Day OpenHK$ 148.0
First Day Change-8.61%
First Day Volume11667400.0
First Day Turnover1675200000.0
Use of Proceeds
1、16.0%或1,005.8百萬港元將用于進一步擴大我們于蘇州的設施網絡乃為我們的未來增長提供必要的支持; 2、10.0%或628.6百萬港元將用于增強我們的美國業務以迎合客戶對Biomere所提供服務日益增長的需求; 3、39.0%或2,451.6百萬港元將用于進一步擴大我們于中國的設施網絡及服務能力; 4、5.0%或314.3百萬港元將用于拓展及深化我們的綜合合同研究組織服務; 5、20%或1,257.2百萬港元將用于進一步實施我們拓寬藥物研發價值鏈上的綜合服務范圍并拓展海外布局的策略; 6、10%或628.6百萬港元將用于營運資金及一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中信证券(香港)有限公司 CE AAK249
Overall Coordinators (3)
CLSA LIMITED CE AAB893 Merrill Lynch (Asia Pacific) Limited CE AAC198 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (9)
CLSA LIMITED CE AAB893 Merrill Lynch (Asia Pacific) Limited CE AAC198 中国国际金融香港证券有限公司 CE AEN894 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 海通国际证券有限公司 CE AAF806 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
Joint Lead Managers (9)
CLSA LIMITED CE AAB893 Merrill Lynch (Asia Pacific) Limited CE AAC198 中国国际金融香港证券有限公司 CE AEN894 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 海通国际证券有限公司 CE AAF806 中银国际亚洲有限公司 CE AET863 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Carmignac Funds 155,046,800 HKD — 2.40% — 6 months 2021-08-26
2 CPE Greater China Enterprises Growth Fund 271,347,000 HKD — 4.10% — 6 months 2021-08-26
3 CRF Investment Holdings Company Limited 232,585,300 HKD — 3.60% — 6 months 2021-08-26
4 Janchor Partners Pan-Asian Master Fund 232,585,300 HKD — 3.60% — 6 months 2021-08-26
5 Lake Bleu Prime Healthcare Master Fund Limited 294,601,000 HKD — 4.50% — 6 months 2021-08-26
6 Octagon Capital Advisors LP 77,523,400 HKD — 1.20% — 6 months 2021-08-26
7 OrbiMed Funds 271,347,000 HKD — 4.10% — 6 months 2021-08-26
8 SCC Growth VI Holdco F, Ltd. 232,585,300 HKD — 3.60% — 6 months 2021-08-26
9 The Valliance Fund 38,761,700 HKD — 0.60% — 6 months 2021-08-26
10 中国国有企业结构调整基金股份有限公司 271,347,000 HKD — 4.10% — 6 months 2021-08-26

Directors & Management

PositionChinese nameEnglish Name
Chairman馮宇霞—
Company Secretary高大鵬、吳卓明—
No director data available.

Major Shareholders

Major Shareholders & Holdings馮宇霞女士及周先生(配偶)為一組控股股東,截至最後實際可行日期合共持有本公司已發行股份約43.37%,其中馮女士直接持有28.17%,周先生直接持有15.20%。
About this page

This page shows Joinn (06127) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect